- Immediate Release (Rythmol)
- Dosage: 150–300 mg q8h
- Formulations: T: 150, 225, 300
- Comments (Metabolism): Contraindicated in patients with ischemic and structural heart disease; adverse events include ventricular tachycardia and HF (L)
- Sustained Release (Rythmol SR)
- Dosage: 225-425 mg q12h
- Formulations: T: 225, 325, 425
- Comments (Metabolism): Contraindicated in patients with ischemic and structural heart disease; adverse events include ventricular tachycardia and HF (L)
Notes:
* following a drug name indicates the drug is available as a generic formulation.
BC following a drug name indicates the drug is listed in the 2023 American Geriatrics Society Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults.
K = renal elimination; L = hepatic elimination